KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Cash & Equivalents (2018 - 2025)

ClearPoint Neuro (CLPT) has disclosed Cash & Equivalents for 13 consecutive years, with $45.9 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 128.36% to $45.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.9 million through Dec 2025, up 128.36% year-over-year, with the annual reading at $45.9 million for FY2025, 128.36% up from the prior year.
  • Cash & Equivalents hit $45.9 million in Q4 2025 for ClearPoint Neuro, up from $38.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $64.9 million in Q1 2021 to a low of $12.4 million in Q1 2025.
  • Historically, Cash & Equivalents has averaged $35.1 million across 5 years, with a median of $30.2 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: soared 293.12% in 2021 and later tumbled 67.56% in 2022.
  • Year by year, Cash & Equivalents stood at $54.1 million in 2021, then tumbled by 48.98% to $27.6 million in 2022, then fell by 16.3% to $23.1 million in 2023, then fell by 12.99% to $20.1 million in 2024, then soared by 128.36% to $45.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for CLPT at $45.9 million in Q4 2025, $38.2 million in Q3 2025, and $41.5 million in Q2 2025.